Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Provention Bio, Inc. (PRVB : NSDQ)
 
 • Company Description   
Provention Bio, Inc. is a biopharmaceutical company. It focuses on development of novel therapeutics and solutions to intercept and prevent immune-mediated disease. The company's product pipeline consists of PRV-031, PRV-6527, PRV-300, PRV-3279 and PRV-101 which are in clinical stage. Provention Bio, Inc. is based in NJ, United States.

Number of Employees: 82

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.91 Daily Weekly Monthly
20 Day Moving Average: 609,595 shares
Shares Outstanding: 64.04 (millions)
Market Capitalization: $250.40 (millions)
Beta: 2.74
52 Week High: $11.49
52 Week Low: $3.40
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.30% -21.50%
12 Week -38.42% -32.30%
Year To Date -30.43% -14.99%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
55 Broad Street 2nd Floor
-
Red Bank,NJ 07701
USA
ph: 908-336-0360
fax: -
rdoody@proventionbio.com http://www.proventionbio.com
 
 • General Corporate Information   
Officers
Ashleigh Palmer - Chief Executive Officer and Director
Thierry Chauche - Chief Financial Officer
Jeffrey Bluestone - Director
Avery Catlin - Director
Sean Doherty - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74374N102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 64.04
Most Recent Split Date: (:1)
Beta: 2.74
Market Capitalization: $250.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.49 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.02 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.63
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 32.69%
vs. Previous Quarter: 14.63%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -19.11%
ROE
03/31/22 - -83.66
12/31/21 - -78.01
09/30/21 - -82.57
ROA
03/31/22 - -69.39
12/31/21 - -66.28
09/30/21 - -70.92
Current Ratio
03/31/22 - 3.39
12/31/21 - 4.44
09/30/21 - 7.46
Quick Ratio
03/31/22 - 3.39
12/31/21 - 4.44
09/30/21 - 7.46
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -5,671.70
12/31/21 - -8,274.70
09/30/21 - -18,020.65
Book Value
03/31/22 - 1.47
12/31/21 - 1.75
09/30/21 - 2.12
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©